Top Page
XRF Scientific Limited
(Sydney:XRF)
XRF Scientific Limited (XRF) vs. iShares MSCI Australia ETF (EWA)
XRF Scientific Limited Business Overview & Revenue Model
XRF Scientific Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.45M | 59.45M | 59.84M | 55.17M | 40.01M | 31.29M |
| Gross Profit | 28.79M | 28.79M | 26.27M | 22.00M | 16.46M | 12.89M |
| EBITDA | 15.63M | 15.63M | 15.32M | 13.22M | 9.44M | 8.05M |
| Net Income | 10.38M | 10.38M | 8.89M | 7.69M | 6.08M | 5.13M |
Balance Sheet | ||||||
| Total Assets | 72.79M | 72.79M | 68.23M | 65.55M | 55.56M | 48.37M |
| Cash, Cash Equivalents and Short-Term Investments | 12.23M | 12.23M | 12.05M | 10.40M | 6.65M | 5.26M |
| Total Debt | 4.41M | 4.41M | 3.38M | 4.31M | 3.51M | 1.44M |
| Total Liabilities | 12.62M | 12.62M | 12.69M | 15.97M | 12.21M | 9.27M |
| Stockholders Equity | 60.17M | 60.17M | 54.89M | 49.25M | 43.48M | 39.10M |
Cash Flow | ||||||
| Free Cash Flow | 8.39M | 8.39M | 6.45M | 7.63M | 2.63M | 3.86M |
| Operating Cash Flow | 10.14M | 10.14M | 8.09M | 8.42M | 3.15M | 4.51M |
| Investing Cash Flow | -2.21M | -2.21M | -1.64M | -782.43K | -1.11M | -652.62K |
| Financing Cash Flow | -7.75M | -7.75M | -4.80M | -3.88M | -648.95K | -2.24M |
XRF Scientific Limited Technical Analysis
XRF Scientific Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$303.14M | 28.61 | 18.05% | 2.27% | -1.09% | 14.88% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
46 Neutral | AU$151.44M | -4.98 | -43.66% | ― | 46.74% | -47.98% | |
36 Underperform | AU$899.56M | -55.32 | -183.07% | ― | ― | 70.81% | |
36 Underperform | AU$282.94M | ― | -6.62% | ― | ― | 72.45% | |
32 Underperform | AU$483.52M | -10.55 | -150.61% | ― | ― | -186.15% |
XRF Scientific Limited Corporate Events
XRF Scientific Limited announced a change in the director’s interest, specifically involving Vance Stazzonelli. The change involved an acquisition of 5,912 ordinary shares through an on-market trade, increasing his total holdings in the company. This adjustment in shareholding reflects ongoing investment and confidence in the company’s future prospects.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited held its 2025 Annual General Meeting, where key resolutions were passed, including the approval of the remuneration report, the re-election of Director David Brown, and the issuance of performance rights to Mr. Vance Stazzonelli. These decisions are expected to strengthen the company’s governance and incentivize leadership, potentially enhancing its operational effectiveness and market competitiveness.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited presented its advanced technology in sample preparation and chemical analysis at its AGM in October 2025. The company’s focus on a wide range of minerals and materials positions it strongly in the mining and manufacturing sectors, enhancing its offerings to commercial labs and research institutions.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited reported a positive performance for the September 2025 quarter, with a 16% increase in revenue and a 7% rise in profit before tax compared to the previous year. The company’s international sales were strong, particularly in Canada, Belgium, and Germany, and it saw significant growth in its Orbis crushers and precious metals products. The company anticipates continued growth in the December quarter, focusing on international sales, new product developments, and M&A opportunities.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited announced a change in the director’s interest, specifically involving David William Kiggins. The change was due to the acquisition of 1,933 ordinary shares under a dividend reinvestment plan, increasing his indirect holdings through Glengarry Estate Pty Ltd. This adjustment reflects the company’s ongoing commitment to aligning leadership interests with shareholder value, potentially impacting stakeholder confidence positively.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has announced a change in the director’s interest, with Frederick Sheppard Grimwade acquiring 11,822 ordinary shares through a dividend reinvestment plan, increasing his total holdings to 563,527 shares. This change reflects the director’s continued confidence in the company’s performance and strategic direction, potentially impacting investor perceptions and stakeholder confidence positively.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has announced the issuance of 661,397 fully paid ordinary securities to be quoted on the Australian Securities Exchange (ASX) as of September 26, 2025. This move is part of a dividend or distribution plan, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with its financial growth.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has announced its Annual General Meeting (AGM) scheduled for October 20, 2025, at the Quest Hotel in Innaloo, WA. The meeting will address key resolutions, including the adoption of the Remuneration Report and the re-election of Mr. David Brown as a director. These resolutions are significant for the company’s governance and strategic direction, impacting shareholder engagement and the company’s leadership structure.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited announced a change in director David Brown’s shareholding, with Brown selling 1,000,000 shares for financial diversification purposes. Despite this sale, Brown has no immediate plans for further sales, and the transaction was executed through an on-market trade. This move reflects Brown’s strategy to diversify his investments, as a significant portion of his holdings are in XRF shares. The announcement, approved by the company’s board, highlights the director’s confidence in the company’s future performance, as he retains a substantial stake.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has issued 385,294 fully paid ordinary shares without disclosure to investors under the Corporations Act 2001. This move complies with relevant legal provisions, and there is no additional information required for investors to assess the company’s financial position or the rights attached to the securities.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has announced the application for the quotation of 385,294 ordinary fully paid securities on the ASX, with an issue date of August 22, 2025. This move is part of previously announced transactions, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with its financial growth.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has announced a proposed issue of 385,294 ordinary fully paid securities, with the issuance date set for August 22, 2025. This move is part of a placement or other type of issue, which could potentially impact the company’s market position by increasing its capital base and providing additional resources for its operations.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited announced an update regarding the earnout payment for Orbis Mining Pty Ltd, highlighting Orbis’ strong financial performance in FY25 with a 20% revenue increase to $7 million and a 39% profit increase to $2.4 million. The earnout payment, amounting to $800,526, was settled through the issuance of 385,294 XRF shares, reflecting the company’s strategic decision to honor the former Orbis shareholders’ request to receive the earnout entirely in shares, thus reinforcing their commitment to XRF.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited announced a change in the director’s interest, specifically involving Vance Stazzonelli. The change includes the conversion of 384,088 performance rights into ordinary shares and the lapsing of 18,415 performance rights. This adjustment reflects the company’s ongoing management of executive incentives and could impact the company’s stock distribution and stakeholder interests.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has announced the application for the quotation of 1,409,597 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from August 21, 2025. This move is part of the company’s strategy to enhance its market presence and provide liquidity for stakeholders, potentially impacting its financial flexibility and shareholder value.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating its commitment to transparency and accountability in its operations. This announcement is significant as it reinforces the company’s dedication to maintaining high governance standards, which is crucial for its reputation and trust among stakeholders.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited’s latest investor presentation highlights their expertise in sample preparation technology and chemical analysis, catering to a wide range of minerals and materials. The company’s focus on advanced analysis techniques positions it as a key player in the mining and manufacturing sectors, potentially influencing market dynamics and stakeholder interests.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has announced a dividend distribution of AUD 0.045 per share for its ordinary fully paid securities, with the record date set for September 12, 2025, and payment scheduled for September 26, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may positively impact its market positioning by reinforcing investor confidence.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited reported a record full-year result for June 2025, with revenue reaching $59.5 million and a net profit after tax of $10.4 million, marking a 17% increase from the previous year. The company’s growth was driven by strong activity in the mining industry and international sales, particularly in Asia, the Americas, and Europe. The Consumables division achieved a record profit before tax of $7.2 million, while the Precious Metals and Capital Equipment divisions also performed well. A final fully franked dividend of 4.5 cents per share was declared, reflecting a 15% increase from last year.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited has released its annual financial report for the year ending June 30, 2025. The report includes comprehensive financial statements and disclosures, reflecting the company’s financial performance and position over the past year. This release is crucial for stakeholders as it provides insights into the company’s financial health and strategic direction.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited reported a slight decline in revenue by 1% to $59.4 million for the year ending June 2025, while net profit after tax increased by 17% to $10.4 million. The company declared a final dividend of 4.5 cents per share, up from 3.9 cents the previous year. Additionally, XRF acquired Labfit Pty Ltd, contributing $536k in revenue and $91k in net profit before tax, enhancing its market position and operational capabilities.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.